LEXINGTON, Mass. & ORLANDO, Fla.--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) today announced results of an interim analysis from the company’s ongoing global patient survival registry, which showed that patients with kidney cancer at intermediate risk of disease recurrence demonstrated an approximately 46 percent lower risk of death when treated with Oncophage® (vitespen) cancer vaccine compared with observation (n = 362; P = 0.036; hazard ratio [HR] = 0.54).
